ID   NCI-H69/LX10
AC   CVCL_2138
SY   H69/LX10
DR   cancercelllines; CVCL_2138
DR   ECACC; 96042331
DR   GEO; GSM1887949
DR   GEO; GSM1888025
DR   Wikidata; Q54908105
RX   PubMed=27247353;
RX   PubMed=28766886;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Sequence variation: Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.Gly106_Arg108del (c.317_325delGGCAACCGT); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:9884; RB1; Simple; p.Glu748Ter (c.2242G>T); ClinVar=VCV000013078; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Glu171Ter (c.511G>T); ClinVar=VCV000634771; Zygosity=Homozygous (from parent cell line).
CC   Omics: Phenotyping; Drug screening.
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Transcriptomics; miRNA profiling; Microarray.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4917; Lung small cell carcinoma
DI   ORDO; Orphanet_70573; Small cell lung cancer
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1579 ! NCI-H69
SX   Male
AG   55Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 22
//
RX   PubMed=27247353; DOI=10.1093/jnci/djw122; PMCID=PMC6279282;
RA   Polley E.C., Kunkel M.W., Evans D., Silvers T.E., Delosh R.M., Laudeman J.,
RA   Ogle C., Reinhart R., Selby M., Connelly J., Harris E., Fer N.,
RA   Sonkin D., Kaur G., Monks A., Malik S., Morris J., Teicher B.A.;
RT   "Small cell lung cancer screen of oncology drugs, investigational
RT   agents, and gene and microRNA expression.";
RL   J. Natl. Cancer Inst. 108:djw122.1-djw122.11(2016).
//
RX   PubMed=28766886; DOI=10.1002/cam4.1131; PMCID=PMC5548882;
RA   Teicher B.A., Silvers T.E., Selby M., Delosh R.M., Laudeman J., Ogle C.,
RA   Reinhart R., Parchment R.E., Krushkal J., Sonkin D., Rubinstein L.,
RA   Morris J., Evans D.;
RT   "Small cell lung carcinoma cell line screen of etoposide/carboplatin
RT   plus a third agent.";
RL   Cancer Med. 6:1952-1964(2017).
//